Menu Search
Equities

Integra Lifesciences Holdings Corp

IL3:BRN

Integra Lifesciences Holdings Corp

Actions
  • Price (CHF)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The Company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, bone grafts, and nerve and tendon repair products.

  • Revenue in USD (TTM)1.56bn
  • Net income in USD-6.54m
  • Incorporated1989
  • Employees3.95k
  • Location
    Integra Lifesciences Holdings Corp1100 Campus RoadPRINCETON 08540United StatesUSA
  • Phone+1 (609) 275-0500
  • Fax+1 (609) 750-4277
  • Websitehttps://www.integralife.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		IART:NSQ since
announced		Transaction
value
Acclarent IncDeal completed13 Dec 202313 Dec 2023Deal completed-42.38%280.00m
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.